Michael D. Cirigliano, MD, FACP Founder's Associate Professor of Medicine Department of Medicine Division of General Internal Medicine Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania Philadelphia, PA
Gary R. Lichtenstein, MD Professor of Medicine Director, Center for Inflammatory Bowel Disease Department of Medicine Division of Gastroenterology Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania Philadelphia, PA
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
Inflammatory bowel disease (IBD), which comprises ulcerative colitis (UC) and Crohn’s disease (CD), is a complex condition that can be difficult to identify and treat. Carefully tailoring and monitoring care is essential because therapeutic goals and strategies differ by disease severity. New data available to clinicians are revising the management paradigm for IBD as well as the definition of deep remission. This activity, intended for internal medicine and primary care clinicians, will review screening, diagnosis, treatment initiation and referral, as well as the management of adverse events.
. Target Audience
This educational activity is designed to meet the needs of internal medicine physicians and other primary care clinicians who treat patients with IBD including physician assistants (PAs) and nurse practitioners (NPs).
Upon completion of this educational activity, the participant should be able to:
Describe appropriate strategies for recognizing the symptoms of and diagnosing IBD.
Discuss treatment goals and current strategies for the management of IBD.
Incorporate adverse event monitoring into routine care visits for patients with IBD.
Recognize the most common extraintestinal manifestations of and comorbidities associated with IBD.
Michael D. Cirigliano, MD, FACP, has no conflicts of interest to disclose.
Gary R. Lichtenstein, MD, discloses the following conflicts of interest
Consultant--Abbott Corporation/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Biotech, Luitpold/American Regent, Pfizer, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB, Warner Chilcott
Research/Grant Support--Ferring, Janssen Biotech, Prometheus Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB, Warner Chilcott
Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.
The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: September 13, 2016
Last review date: September 13, 2016
Expiration date: September 13, 2017 Commercial Support Statements
This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.
* Click "Start Program" and log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 80%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2016 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, or Salix Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.